{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:12:46Z","timestamp":1788412366925,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"DOI":"10.7759\/cureus.97448","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:34:54Z","timestamp":1763746494000},"source":"Crossref","is-referenced-by-count":1,"title":["Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report"],"prefix":"10.7759","author":[{"given":"Yashwanth","family":"Suresh Babu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Jayagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan JR","year":"1989","unstructured":"Riordan JR, Rommens JM, Kerem B, et al.. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989, 245:1066-73. 10.1126\/science.2475911","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn JS","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet. 2016, 388:2519-31. 10.1016\/S0140-6736(16)00576-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton PG","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, et al.. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019, 381:1809-19. 10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-025-00303-4","article-title":"Impact of CFTR modulators on longitudinal cystic fibrosis survival and mortality: review and secondary analysis","volume":"11","author":"Rubin JL","year":"2025","unstructured":"Rubin JL, McKinnon C, Pedra GG, Morgan DA, Zweig K, Liou TG. Impact of CFTR modulators on longitudinal cystic fibrosis survival and mortality: review and secondary analysis. Pulm Ther. 2025, 11:365-86. 10.1007\/s41030-025-00303-4","journal-title":"Pulm Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran A","year":"2009","unstructured":"Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009, 32:1626-31. 10.2337\/dc09-0586","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings VA","year":"2008","unstructured":"Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008, 108:832-9. 10.1016\/j.jada.2008.02.020","journal-title":"J Am Diet Assoc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery S","year":"2022","unstructured":"Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK. Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros. 2022, 21:777-83. 10.1016\/j.jcf.2022.03.010","journal-title":"J Cyst Fibros"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an Evidence Analysis Center systematic review","volume":"121","author":"Bailey J","year":"2021","unstructured":"Bailey J, Rozga M, McDonald CM, et al.. Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an Evidence Analysis Center systematic review. J Acad Nutr Diet. 2021, 121:1364-78. 10.1016\/j.jand.2020.03.014","journal-title":"J Acad Nutr Diet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15844","article-title":"Cystic fibrosis-related diabetes develops from a combination of insulin secretion defects and insulin resistance","volume":"26","author":"Bolduc M\u00c8","year":"2024","unstructured":"Bolduc M\u00c8, Potter KJ, Olmos M, et al.. Cystic fibrosis-related diabetes develops from a combination of insulin secretion defects and insulin resistance. Diabetes Obes Metab. 2024, 26:4744-52. 10.1111\/dom.15844","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart NJ","year":"2018","unstructured":"Hart NJ, Aramandla R, Poffenberger G, et al.. Cystic fibrosis-related diabetes is caused by islet loss and inflammation. JCI Insight. 2018, 3:4. 10.1172\/jci.insight.98240","journal-title":"JCI Insight"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0399","article-title":"Effects of GLP-1 and GIP on islet function in glucose-intolerant, pancreatic-insufficient cystic fibrosis","volume":"71","author":"Nyirjesy SC","year":"2022","unstructured":"Nyirjesy SC, Peleckis AJ, Eiel JN, et al.. Effects of GLP-1 and GIP on islet function in glucose-intolerant, pancreatic-insufficient cystic fibrosis. Diabetes. 2022, 71:2153-65. 10.2337\/db22-0399","journal-title":"Diabetes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01198-4","article-title":"Efficacy and safety of tirzepatide, dual GLP-1\/GIP\u00a0receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Zhou Q","year":"2023","unstructured":"Zhou Q, Lei X, Fu S, et al.. Efficacy and safety of tirzepatide, dual GLP-1\/GIP\u00a0receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023, 15:222. 10.1186\/s13098-023-01198-4","journal-title":"Diabetol Metab Syndr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes","volume":"107","author":"Pirro V","year":"2022","unstructured":"Pirro V, Roth KD, Lin Y, et al.. Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2022, 107:363-78. 10.1210\/clinem\/dgab722","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","unstructured":"Nutrition in Children and Adults Clinical Care Guidelines | Cystic Fibrosis Foundation. (2025). Accessed. September 27, 2025: https:\/\/www.cff.org\/medical-professionals\/nutrition-children-and-adults-clinical-care-guidelines."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-025-09991-4","article-title":"Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis","volume":"9","author":"Masson W","year":"2025","unstructured":"Masson W, Lobo M, Nogueira JP, Barbagelata L, Touzas P, Fr\u00edas JP. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2025, 9:4. 10.1007\/s11154-025-09991-4","journal-title":"Rev Endocr Metab Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/children10121879","article-title":"An update in cystic fibrosis-related diabetes in children and adolescents","volume":"10","author":"Anton-P\u0103duraru DT","year":"2023","unstructured":"Anton-P\u0103duraru DT, Murgu AM, Donos MA, et al.. An update in cystic fibrosis-related diabetes in children and adolescents. Children (Basel). 2023, 10:9. 10.3390\/children10121879","journal-title":"Children (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2024.100375","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review","volume":"38","author":"Ahmed A","year":"2024","unstructured":"Ahmed A, Ankireddypalli A, Harindhanavudhi T, Moran A, Moheet A. Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review. J Clin Transl Endocrinol. 2024, 38:100375. 10.1016\/j.jcte.2024.100375","journal-title":"J Clin Transl Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.08.005","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","volume":"24","author":"Park S","year":"2025","unstructured":"Park S, Jain R, Mirfakhraee S. Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis. J Cyst Fibros. 2025, 24:40-6. 10.1016\/j.jcf.2024.08.005","journal-title":"J Cyst Fibros"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434323-redefining-cystic-fibrosis-related-diabetes-management-with-tirzepatide-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:34:55Z","timestamp":1763746495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434323-redefining-cystic-fibrosis-related-diabetes-management-with-tirzepatide-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.97448","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}